Nondepolarizing neuromuscular blockade





A 22-year-old woman presented for abdominoplasty. Her weight was 75 kg and her height was 160 cm. Past medical history was significant for seizure disorder treated with phenytoin 100 mg twice daily. She had been seizure-free for the past 6 years. She had never received anesthesia before. Her plasma phenytoin level was within therapeutic range. After placement of monitors, fentanyl 100 μg and midazolam 2 mg were administered. General anesthesia was induced with propofol 200 mg, followed by vecuronium 8 mg for neuromuscular blockade. Intubating conditions were excellent. Anesthesia was maintained with isoflurane 2% in 70% oxygen/30% nitrous oxide. The end-tidal isoflurane concentration was 1.2%. During preparation of the abdomen 10 minutes later, she moved. Bispectral index was 45. Train-of-four stimulation of the ulnar nerve at the wrist demonstrated four twitches of the adductor pollicis brevis muscle.





Describe how nondepolarizing neuromuscular blocking drugs produce skeletal muscle relaxation.


Nondepolarizing neuromuscular blocking drugs (NMBDs) produce relaxation of voluntary (skeletal or striated) muscles by the following mechanisms:




  • Inhibit the effect of acetylcholine by competing with it as they bind to the alpha subunit of the nicotinic acetylcholine receptor at the postjunctional membrane



  • Block prejunctional acetylcholine receptors at the motor nerve terminal, decreasing acetylcholine release in response to motor nerve stimulation



  • Noncompetitively block open postjunctional acetylcholine channels






How do nondepolarizing neuromuscular blocking drugs differ from one another?


Although numerous NMBDs are available for clinical use, structurally they fall into one of two types: steroid-based or benzylisoquinolinium compounds. Steroidal NMBDs include rocuronium, vecuronium, pancuronium, and pipecuronium. Benzylisoquinolinium compounds include atracurium, cisatracurium, mivacurium (no longer available in the United States), and doxacurium. NMBDs are usually classified according to their durations of action as short-acting, intermediate-acting, or long-acting ( Table 21-1 ). The choice of NMBDs depends on several factors, including onset time, duration of action, elimination time, potency, and route or routes of elimination. In addition, some NMBDs may have desirable or undesirable effects on the cardiovascular and respiratory systems. These effects may be mediated by the autonomic nervous system or histamine receptors or both.



TABLE 21-1

Properties of Nondepolarizing Neuromuscular Blocking Drugs




















































































Drug ED 95 (mg/kg) Onset Time/Clinical RI 25–75 (min) Elimination Half-Life * (min) Route(s) of Elimination Cardiovascular Effects Histamine Release Autonomic Ganglion Block Intubating Dose (mg/kg)
Atracurium 0.2 Slow/11–23 20 Nonenzymatic ester hydrolysis
Hoffman elimination
None Skin flushing
Hypotension
Bronchospasm
None 0.5–0.6
Cisatracurium 0.05 Slow/11–23 20 Nonenzymatic ester hydrolysis
Hoffman elimination
None None None 0.15–0.2
Mivacurium 0.07 Slow/6–8 18 Hydrolysis by plasma cholinesterase None Yes None 0.2–0.25
Pancuronium 0.07 Slow/24 145 Renal; some hepatic Tachycardia None None 0.08–0.12
Rocuronium 0.3 Rapid/10–15 60–75 Hepatic; some renal None None None 0.6–1; 1.2 (RSI)
d-Tubocurarine 0.5 Slow/25–35 80 Renal; minimal hepatic Hypotension
Bradycardia
Skin flushing Yes 0.5–0.6
Vecuronium 0.05 Slow/10–15 62 Hepatic; some renal None None None 0.1–0.2

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 14, 2019 | Posted by in ANESTHESIA | Comments Off on Nondepolarizing neuromuscular blockade

Full access? Get Clinical Tree

Get Clinical Tree app for offline access